What is Day One Biopharmaceuticals Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Day One Biopharmaceuticals's Probability of Financial Distress (%) is 0.06%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Day One Biopharmaceuticals's Probability of Financial Distress (%)
For the Biotechnology subindustry, Day One Biopharmaceuticals's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Probability of Financial Distress (%) falls into.
Day One Biopharmaceuticals Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -7.47 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.06% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Executives
| York Charles N Ii |
officer: COO, CFO and Secretary |
901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746 |
| Samuel C. Blackman |
officer: Chief Medical Officer |
395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
| Jeremy Bender |
director, officer: Chief Executive Officer |
395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
| Ai Day 1 Llc |
10 percent owner |
40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
| Julie Papanek Grant |
director |
2765 SAND HILL ROAD, MENLO PARK CA 94025 |
| Canaan Xi L.p. |
10 percent owner |
2765 SAND HILL RD, MENLO PARK CA 94025 |
| Garry A Nicholson |
director |
C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
| Atlas Venture Opportunity Fund Ii, L.p. |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Michael Gladstone |
director |
395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
| Atlas Venture Fund Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Takeda Pharmaceutical Co Ltd |
10 percent owner |
1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
| Takeda Pharmaceuticals U.s.a., Inc. |
10 percent owner |
ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
| Takeda Ventures, Inc. |
10 percent owner |
9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
| J. Scott Garland |
director |
210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| John A. Josey |
director |
C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235 |
Day One Biopharmaceuticals (Day One Biopharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DAWN has been successfully added to your